Novo says its next-gen obesity drug tops Lilly rival in late-stage study

Sept 21 (Reuters) – Novo ​Nordisk ‌said on Monday its ‌next-generation ​experimental ⁠drug ⁠had achieved an estimated average ​weight ⁠loss ⁠of ​12.4% in ​a late-stage ‌trial and that ⁠it was superior to ⁠Eli ‌Lilly’s ⁠drug.

(Reporting ​by ‌Sriparna ​Roy in ⁠Bengaluru; Editing by Shinjini ​Ganguli)